These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Modification of fertility of the male by antiandrogens].
    Author: Moltz L, Neumann F, Hammerstein J.
    Journal: Gynakologe; 1980 Mar; 13(1):18-32. PubMed ID: 6219927.
    Abstract:
    Cytoproterone acetate (CPA) type antiandrogens have been found to inhibit all androgen-dependent function (also reproductive ability) in man and male experimental animals. In animals a CPA dose can be established which reduces spermatogenesis but leaves hormone regulation unchanged. It is not possible to selectively affect epididymal sperm maturation. Initial clinical experience with high-dosage CPA therapy for fertility inhibition was gained from patients with sex deviations. Oral administration of 100-300 mg CPA daily caused high degree of oligospermia within a few weeks; whether longterm therapy (1 1/2-2 years) leads to desensitization and subsequent increase of gonadotropins and androgens with recovered fertility has not yet been established. Sex drive is strongly affected by high-dosage therapy, hence not desirable for male fertility control. A World Health Organization study used a low-dosage daily oral CPA intake of 5-20 mg over a period of 12-26 weeks. Men under 30 years of age tolerated this daily use without side effects; men over 35 years complained of diminished libido and potency. These CPA dosages reduced sperm quality to subfertile values; sperm count, shape, and motility were affected but no azoospermia was achieved. In vitro and in vivo sperm migration is strongly affected. All somatic and psychosexual changes are reversible. In contrast to animal studies oral use of 10 mg CPA daily modifies endocrinologic processes in man. There is a decrease in FSH and LH synthesis and release; this demonstrates a stronger gestagen effect than the antiandrogen effect of CPA. There is an even greater reduction in plasma testosterone and dihydrotestosterone levels. CPA also modifies testicular androgen production; changes in spermatogenesis can be attributed to a reduced androgen output and to a ect CPA effect on the tubules. A distinct modification of spermatogenesis and posttesticular sperm maturation processes cannot be demonstrated in the dosage range studied. Current studies do not allow a conclusive evaluation of the applicability of CPA for fertility control in men. Longterm studies with smaller CPA dosages are needed.
    [Abstract] [Full Text] [Related] [New Search]